GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-9.66%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$886M
AUM Growth
+$886M
(-15%)
Cap. Flow
-$82.1M
Cap. Flow
% of AUM
-9.27%
Top 10 Holdings %
Top 10 Hldgs %
70.05%
Holding
43
New
8
Increased
12
Reduced
7
Closed
10
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$31.5M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
$31.4M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$29.5M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$27M |
| 5 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$26.5M |
Top Sells
| 1 |
Iovance Biotherapeutics
IOVA
|
$78.7M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$49.3M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$41.7M |
| 4 |
DERM
Dermira, Inc.
DERM
|
$39.7M |
| 5 |
TG Therapeutics
TGTX
|
$28.3M |
Sector Composition
| 1 | Healthcare | 97.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Axsome Therapeutics
AXSM
$6.09B
| $5.89M | 0.62% |
100,100
+99,846
| +39,309% | +$5.87M |
|
27
Arvinas
ARVN
$580M
| $4.77M | 0.5% |
118,330
-431,670
| -78% | -$17.4M |
|
28
VYNE Therapeutics
VYNE
$8.09M
| $4.43M | 0.46% |
1,652,013
| – | – |
|
29
Sangamo Therapeutics
SGMO
$161M
| $4.04M | 0.42% |
+633,505
| New | +$4.04M |
|
30
Kura Oncology
KURA
$732M
| $1.79M | 0.19% |
179,700
-674,077
| -79% | -$6.71M |
|
31
CytomX Therapeutics
CTMX
$350M
| $1.07M | 0.11% |
+139,718
| New | +$1.07M |
|
32
Neurogene
NGNE
$284M
| $459K | 0.05% |
+40,347
| New | +$459K |
|
|
ZGNX
33
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-420,000
| Closed | -$21.9M |
|
|
DERM
34
DELISTED
Dermira, Inc.
DERM
| – | – |
-2,621,333
| Closed | -$39.7M |
|
35
Tandem Diabetes Care
TNDM
$834M
| – | – |
-250,000
| Closed | -$14.9M |
|
|
OPTN
36
DELISTED
OptiNose
OPTN
| – | – |
-1,181,834
| Closed | -$10.9M |
|
37
Ionis Pharmaceuticals
IONS
$9.64B
| – | – |
-65,000
| Closed | -$3.93M |
|
38
Insmed
INSM
$30.3B
| – | – |
-97,359
| Closed | -$2.33M |
|
|
GNFT
39
Genfit
GNFT
$198M
| – | – |
-207,766
| Closed | -$4.14M |
|
40
DexCom
DXCM
$30.9B
| – | – |
-26,100
| Closed | -$5.71M |
|
41
BridgeBio Pharma
BBIO
$9.91B
| – | – |
-78,400
| Closed | -$2.75M |
|
42
Aurinia Pharmaceuticals
AUPH
$1.58B
| – | – |
0
| – | – |
|
43
Atara Biotherapeutics
ATRA
$88.7M
| – | – |
-70,000
| Closed | -$1.15M |
|